News EULAR 26 hears of treatment advances in lupus Three trials of potentially first-in-class therapies for J&J, UCB/Biogen, and Merck KGaA at EULAR have offered hope of new targeted drugs for lupus.
News Amid tough competition, Novartis makes case for rheumatology... Swiss pharma hopes to bounce back from Q1 sales disappointment
News Janssen's RA candidate among hot topics at EULAR But attendees warned to expect "oceanic" weather.
News Tenax trounced by phase 3 heart failure readout Shares in Tenax 85% of their value after its drug for patients with pulmonary hypertension caused by a form of heart failure flunked a phase 3 trial.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.